ArticleFrontiers in neurology2025
Endovascular stenting for symptomatic atherosclerotic stenosis of the anterior and posterior cerebral arteries: a case series.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Symptomatic intracranial atherosclerotic stenosis (sICAS) in the anterior cerebral artery (ACA) or posterior cerebral artery (PCA) may result in disability even with the best pharmacological intervention. There is a paucity of evidence regarding endovascular procedures for sICAS associated with ACA or PCA. Methods: From January 2022 to December 2024, 12 patients with medically refractory sICAS associated with ACA or PCA, who received percutaneous transluminal angioplasty and stenting (PTAS), were included for analysis. Exclusion criteria included (1) non-atherosclerotic stenosis, concomitant infarcts in other vascular territories, antiplatelet contraindication, a baseline modified Rankin Scale (mRS) score of 3 or above, and (2) concomitant disease with survival < 2 years. sICAS with 70-99% stenosis and 2 or more strokes in the same vascular territory, with at least 1 stroke occurring during medical therapy, is considered refractory to medical treatment. Clinical data from these patients were collected and analyzed. Results: In 12 patients, three stenotic lesions were in the A2 segment of the ACA, and 9 were in the P1 or P2 segments of the PCA (stenosis > 70%). All lesions were treated with PTAS (1 with the NOVA intracranial sirolimus-eluting stent system, 1 with the Neuroform EZ stent, and 10 with the Neuroform Atlas stents), achieving a 100% technical success rate (residual stenosis < 30%). Dissection with unrestricted flow occurred in 1 patient (1/12) during stent placement, which disappeared 12 months later. The follow-up time ranged from 3 to 18 months (≥ 6 months in 11 patients). In the follow-up, 1 patient suffered a recurrent stroke (8.3, 95% CI: 0.21-38.5%) due to the cessation of antiplatelet and anticoagulant medication 2 months after endovascular stenting; however, the remaining 11 patients exhibited a fair outcome with a modified Rankin Scale of 1 or 0 (91.67, 95% CI: 61.5-99.8%) and no in-stent stenosis (0, 95% CI: 0-26.5%). Conclusion: Endovascular stenting with newer self-expanding stents may be feasible and procedurally safe for patients with medically refractory sICAS associated with ACA or PCA. However, this therapy should not be treated as generalizable or low-risk. Further research is necessary for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.